Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Hyloris On Track To Meet 2024 Target During Half-Year Update

Company Aims To Expand Its Portfolio To 30 Products By 2024

Train approaching train station on top of Mount Rigi in canton of Schwyz, Switzerland — Hyloris remains on track to meet its 2024 ambitions, according to the company's CEO • Source: Shutterstock

Related Content

Hyloris Buys Out Maxigesic IV Royalty Rights From Alter Pharma

Jun 28 2021

Hyloris And Purna Strike Value-Added Development Deal

Sep 19 2025

Hyloris Teams Up With Vaneltix For Value-Added Interstitial Cystitis Pain Treatment

Dec 20 2021

FDA Asks Hyloris For More Data On Maxigesic IV

Jul 05 2022

Hyloris Raises €15m In Private Equity Offering

Apr 19 2022

Related Companies

Hyloris Pharmaceuticals SA

Vaneltix Pharma, Inc.

Alter Pharma Group

Additional Topics

Sales & Earnings Strategy Value-Added Medicines BioPharmaceutical

More from Earnings

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window